MMP9 and neoplasm: Under MT treatment, the serum level of MMP2 (214±9.8 ng/ml) was increased compared to MT (−) group (165±7.8 ng/ml) (Fig. 4A, p = 0.0078) and also MMP9 was increased by MT treatment (25.5±1.81 ng/ml) rather than MT (−) group (16.9±1.40 ng/ml) (Fig. 4B, p = 0.0206) indicated that the treatment of MT on OS tumor induced the risk of metastasis through increasing the expression of MMPs.